Pr. Ali MIRAZIMI (Unit of Clinical Microbiology, dept of Labortory medicin, karolinska Institute; Senior Expert Scientist, Public Health Agency of SWEDEN) 

Hôte : Vincent Legros & François-Loïc Cosset

 

Crimean-Congo Hemorrhagic Fever (CCHF) is a severe viral illness with a high mortality rate, caused by the Crimean-Congo Hemorrhagic Fever Virus (CCHFV). Despite its severity, the pathogenesis of CCHFV remains insufficiently understood, with the intricate interplay of viral and cellular factors likely contributing to the molecular progression of the disease. Our ongoing efforts to unravel the key steps in this interaction aim to yield crucial insights, potentially unveiling targets for therapeutic interventions. The urgency to develop a secure and efficacious vaccine against CCHFV is paramount to curbing the impact of outbreaks and safeguarding vulnerable populations. A spectrum of vaccine platforms, ranging from inactivated vaccines to genetic and subunit vaccines, is currently under scrutiny. Our focus revolves around pinpointing viral antigens capable of eliciting a robust and protective immune response while minimizing the risk of potential side effects.In summary, as we grapple with the complexities of CCHFV pathogenesis, the pursuit of a comprehensive understanding underscores the significance of identifying potential therapeutic targets. Simultaneously, the race to develop a safe and effective vaccine remains imperative in our quest to mitigate the repercussions of CCHF outbreaks and shield those most susceptible to its severe consequences.